At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 40 enrolled
Drug / intervention
Sugammadex (4 mg/Kg)drug
Likely dose
Sugammadex (4 mg/Kg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Sugammadex (Bridion™) in the Reversal of Profound Rocuronium-induced Neuromuscular Blockade in Patients With End-stage Renal Failure: Comparison With Healthy Patients
In Brief
A Phase 4 clinical trial evaluating Sugammadex (4 mg/Kg) for Kidney Failure, Chronic and Neuromuscular Blockade. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether sugammadex reverses a profound neuromuscular blockade induced by rocuronium in patients with end-stage renal disease just as effectively and safely as it does in patients with normal renal function.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Failure, Chronic, Neuromuscular Blockade
CountriesBrazil
CollaboratorsHospital General Universitario Santa Lucía
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2011
Primary CompletionJan 2012
First PostedFeb 2013
TodayJul 2026
First PostedFeb 7, 2013
Enrollment StartOct 1, 2011
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 13.4 years ago
Interventions
Sugammadex (4 mg/Kg)drug
Sugammadex administered at the end of surgical procedure, once skin suture had been finished, to reverse profound neuromuscular blockade induced and maintained with rocuronium